UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-42749
POMDOCTOR LIMITED
(Exact name of registrant as specified in its
charter)
Yongxu Industrial Park No. 19-23 Hejing Road
Dongsha Street, Liwan District
Guangzhou 510000
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Nasdaq Compliance with Minimum Bid Price Requirement
On November 5, 2026, POMDOCTOR LIMITED (the “Company”)
received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that
the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) and is therefore
in compliance with the continued listing requirements of the Nasdaq Global Market.
As a result, the hearing before the Nasdaq Hearings Panel that had
been scheduled for November 12, 2026 has been cancelled. The Company’s securities will continue to be listed and traded on the Nasdaq
Global Market.
On November 6, 2026, the Company issued a press release announcing
its receipt of the Nasdaq notification. A copy of the press release is furnished as Exhibit 99.1 to this Form 6-K.
The information contained in this Report on Form 6-K, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing
of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference
in such filing.
EXHIBIT INDEX
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated November 6, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
POMDOCTOR LIMITED |
| |
|
|
| Date: November 6, 2026 |
|
|
|
By: |
/s/ Zhenyang Shi |
| |
Name: |
Zhenyang Shi |
| |
Title: |
Chairman and Chief Executive Officer |
Exhibit 99.1
POMDOCTOR LIMITED Regains Compliance with Nasdaq
Bid Price Requirement
GUANGZHOU, China, November 6, 2026 /PRNewswire/
-- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing
AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on November 5, 2026, the Company received
a letter (the “Compliance Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has
regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1).
As a result, the hearing before the Nasdaq Hearings
Panel originally scheduled for November 12, 2026 has been cancelled.
As previously disclosed, on October 6, 2026, the
Company received a staff delisting determination letter from Nasdaq indicating that the closing bid price of the Company’s securities
had been below $1.00 per share for 30 consecutive business days.
With Nasdaq’s confirmation of compliance, the
Company’s Class A ordinary shares will continue to be listed and traded on Nasdaq under the ticker symbol “POM.”
About POMDOCTOR LIMITED
POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare
company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician
resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more
personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network,
POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and
create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company’s
website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking
statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current
expectations and projections about future events that the Company believes may affect its financial condition, results of operations,
business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,”
“believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,”
“plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions.
The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events
or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations
expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct,
and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the Company’s filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
